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feeOBJECTIVES The aim of this study was to test the hypothesis that invasive coronary function testing at time of
angiography could help stratify management of angina patients without obstructive coronary artery disease.
BACKGROUND Medical therapy for angina guided by invasive coronary vascular function testing holds promise, but the
longer-term effects on quality of life and clinical events are unknown among patients without obstructive disease.
METHODS A total of 151 patients with angina with symptoms and/or signs of ischemia and no obstructive coronary artery
disease were randomized to stratifiedmedical therapy guided by an interventional diagnostic procedure versus standard care
(control group with blinded interventional diagnostic procedure results). The interventional diagnostic procedure–facilitated
diagnosis (microvascular angina, vasospastic angina, both, or neither) was linked to guideline-based management.
Pre-specified endpoints included 1-year patient-reported outcome measures (Seattle Angina Questionnaire, quality of life
[EQ-5D]) and major adverse cardiac events (all-cause mortality, myocardial infarction, unstable angina hospitalization or
revascularization, heart failure hospitalization, and cerebrovascular event) at subsequent follow-up.
RESULTS Between November 2016 and December 2017, 151 patients with ischemia and no obstructive coronary artery
disease were randomized (n ¼ 75 to the intervention group, n ¼ 76 to the control group). At 1 year, overall angina
(Seattle Angina Questionnaire summary score) improved in the intervention group by 27% (difference 13.6 units; 95%
confidence interval: 7.3 to 19.9; p < 0.001). Quality of life (EQ-5D index) improved in the intervention group relative to
the control group (mean difference 0.11 units [18%]; 95% confidence interval: 0.03 to 0.19; p ¼ 0.010). After a median
follow-up duration of 19 months (interquartile range: 16 to 22 months), major adverse cardiac events were similar be-
tween the groups, occurring in 9 subjects (12%) in the intervention group and 8 (11%) in the control group (p ¼ 0.803).
CONCLUSIONS Stratified medical therapy in patients with ischemia and no obstructive coronary artery disease leads to
marked and sustained angina improvement and better quality of life at 1 year following invasive coronary angiography.
(Coronary Microvascular Angina [CorMicA]; NCT03193294) (J Am Coll Cardiol Intv 2020;13:33–45)
© 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).N 1936-8798 https://doi.org/10.1016/j.jcin.2019.11.001
m the aWest of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, United Kingdom; bBritish Heart
undation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow,
sgow, United Kingdom; cGosford Hospital, NSW Health, Gosford, Australia; dRobertson Centre for Biostatistics, Institute of
alth and Wellbeing, University of Glasgow, Glasgow, United Kingdom; and the eUniversity Hospital Hairmyres, East Kilbride,
ited Kingdom. This investigator-initiated clinical trial was funded by the British Heart Foundation (PG/17/2532884, RE/13/5/
177, and RE/18/6134217). Dr. Berry is employed by the University of Glasgow, which holds consultancy and research agreements
th Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Coroventis, GlaxoSmithKline, HeartFlow, Menarini, Opsens, Philips,
d Siemens Healthcare. Dr. Oldroyd has received consulting and speaking fees from Abbott Vascular and Boston Scientific. Dr.
tkins has received consulting and speaking fees from Boston Scientific. Dr. Rocchiccioli has received consulting and speaking
s from AstraZeneca. Dr. Robertson has received educational support from Abbott Vascular and speaking fees from AstraZeneca.
ABBR EV I A T I ON S
AND ACRONYMS
ACh = acetylcholine
BP = blood pressure
CAD = coronary artery disease
CFR = coronary flow reserve
CI = confidence interval
FFR = fractional flow reserve
IDP = interventional diagnostic
procedure
MACE = major adverse cardiac
event(s)
MVA = microvascular angina
RR = relative risk
SAQ = Seattle Angina
Questionnaire
SAQSS = Seattle Angina
Questionnaire summary score
VSA = vasospastic angina
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34C oronary angiography is routinelyperformed for the investigation ofangina. However, up to one-half of
all patients with angina have symptoms
and/or signs of ischemia and no obstructive
coronary artery disease (CAD) (1). This large,
undifferentiated subgroup includes patients
with microvascular angina (MVA) and/or
vasospastic angina (VSA). These conditions
are associated with high morbidity (2),
impaired quality of life (3), and considerable
use of health resources (4). Furthermore,
impaired coronary vasomotion and the pro-
pensity to myocardial ischemia may increase
longer-term risk for major adverse cardiac
events (MACE) (5,6).SEE PAGE 46In the CorMicA (Coronary Microvascular
Angina) trial involving patients withischemia and no obstructive CAD, we found that an
interventional diagnostic procedure (IDP) to rule in or
rule out a disorder of coronary vasomotion was
feasible and useful. Angina improved more at
6 months in patients whose IDP results were dis-
closed compared with the blinded control group. We
hypothesized that stratified medicine in patients with
angina undergoing invasive coronary angiography
would benefit patients in the longer term. We thus
performed a pre-specified analysis of patient-
reported outcome measures at 1 year and assessed
longer-term MACE.METHODS
STUDY DESIGN. The British Heart Foundation Cor-
MicA trial design and 6-month results have been
previously published (7,8). The study is an
investigator-initiated, parallel-group, randomized,
sham-controlled trial with blinded outcome assess-
ment. We recruited patients with angina without
obstructive coronary disease who were randomized
immediately after angiography to the intervention
(IDP to identify coronary vasomotion disorders with
stratified medical therapy of endotypes) or a control
group (blinded invasive coronary function testing
with standard-care antianginal agents guided by the
attending cardiologist).as acted as an advisor for Novartis. Dr. McEntegart has a procto
s. All other authors have reported that they have no relationship
received November 4, 2019; revised manuscript received NovemPARTICIPANTS. We screened elective adult referrals
to 2 large regional hospitals (Golden Jubilee National
Hospital and Hairmyres Hospital) providing invasive
cardiac services to all patients in the west of Scotland
(population 2.5 million). Outpatients undergoing
clinically indicated, elective diagnostic coronary
angiography as standard of care for the investigation
of angina (definite or probable as defined by the Rose
angina questionnaire) were screened and invited to
participate (Figure 1) (9). Exclusion criteria were a
noncoronary indication for invasive angiography
(e.g., valve disease) and inability to give informed
consent. Following the provision of informed con-
sent, participants were enrolled on the cardiology
ward prior to angiography. Demonstration of
obstructive CAD ($50% diameter stenosis and/or
fractional flow reserve [FFR] #0.80) during coronary
angiography was an exclusion criterion, but these
patients entered a registry for ancillary studies. The
West of Scotland Research Ethics Committee
approved the study (REC 1 reference 16/WS/0192).
RANDOMIZATION, GROUPS, AND MASKING. Eligible
patients were randomized immediately following
angiography 1:1 to the intervention group (IDP plus
medical therapy stratified according to IDP results) or
control group (IDP performed but results not dis-
closed [sham]; standard care medical therapy ac-
cording to physician preference). In other words, all
participants underwent the IDP. The results were
disclosed to the attending cardiologist in the inter-
vention group and not disclosed in the control group.
In the intervention group, the cardiologist reap-
praised the initial diagnosis on the basis of coronary
angiography and could change the diagnosis with
linked therapy decisions. In the control group, man-
agement was guided by coronary angiography and all
of the other available medical information, but not
the IDP results. Written guidance informed by prac-
tice guidelines was provided to physicians in both
groups allowing treatment on the basis of the physi-
cians’ working diagnoses. This included using results
of the IDP if available (Online Table 1) (10).
BLINDING AND ADHERENCE. Patients in the control
group had their IDPs performed in the same way as
those in the intervention group, except that the re-
sults were not disclosed to the treating cardiologists.
Details of the blinding procedure have been describedring agreement with Boston Scientific and Vascular
s relevant to the contents of this paper to disclose.
ber 7, 2019, accepted November 7, 2019.
FIGURE 1 CorMicA Trial Profile According to CONSORT Requirements
The total number of patients randomized was 151 with analysis according to intention-to- treat. There was 98% completion of the primary efficacy endpoint assessment
at 6 months and 94% at one year.
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35(7,8). The outcome assessors and statisticians were
blinded to treatment group allocation.
IDP. The purpose of the IDP was to identify disorders
of coronary vasomotion: MVA, VSA, both, or none.
Full details of the guidewire-based IDP assessment
during adenosine-induced hyperemia and acetylcho-
line (ACh) provocation are detailed in the
Online Appendix.
DEFINITIONS OF ENDOTYPES. Diagnosis of a coro-
nary vasomotion disorder (MVA, VSA, both, or none)
was linked to consensus guideline-based pharmaco-
logical and nonpharmacological management (Online
Table 1). A diagnosis of VSA required that 3 conditions
be satisfied during ACh testing: 1) clinically signifi-
cant epicardial vasoconstriction ($90%); 2) repro-
duction of the usual chest pain; and 3) ischemic
electrocardiographic changes (11). MVA was defined
according to standardized Coronary Vasomotion Dis-
orders International Study Group diagnostic criteria:
symptoms of myocardial ischemia, unobstructed
coronary arteries, and proven coronary microvascular
dysfunction (any of abnormal index of microcircula-
tory resistance, coronary flow reserve [CFR], or
microvascular spasm to ACh; web appendix ondefinitions) (9). Diagnosis of coronary microvascular
spasm required provocation and reproduction of
anginal symptoms, ischemic electrocardiographic
shifts, but no epicardial spasm during ACh testing
(11). A diagnosis of noncardiac chest pain required no
obstructive epicardial CAD (FFR >0.80) and an
absence of evidence of any coronary vasomotion
disorder (CFR $2.0, index of microcirculatory
resistance <25, and negative results on ACh testing).
STRATIFIED MEDICAL THERAPY. After randomiza-
tion and completion of the diagnostic intervention,
research staff members invited the cardiologists to
consider the new findings and re-evaluate the diag-
nosis and treatment plan initially made on the basis
of angiography alone. The attending cardiologists in
both of the groups were provided with written man-
agement guidance specific for each endotype and
informed by practice guidelines to facilitate person-
alized treatment that was specifically aligned to their
final diagnosis (Online Appendix) (10). For example,
the first-line therapy for MVA incorporates beta-
blockers, and nitrates were not recommended,
whereas calcium-channel blockers and consideration
of long-acting nitrates were advocated for VSA.
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36Standardized letters specific for each endotype were
sent to the community-based general practitioners
with advice on tailoring and optimizing treatment
(including nonpharmacological and lifestyle mea-
sures) in line with the final diagnosis (Online
Appendix). Standard care for patients in the control
group consisted of guideline-directed medical ther-
apy and antianginal therapies according to the pref-
erence of the attending cardiologist. To mitigate bias,
contacts with participants were standardized be-
tween the groups, and all of the participants were
managed by the point-of-care clinicians and not the
research team.
PATIENT-REPORTED OUTCOME MEASURES AND
HEALTH-RELATED QUALITY OF LIFE. The Seattle
Angina Questionnaire (SAQ) is a self-administered,
disease-specific measure of angina severity that is
valid, reproducible, and sensitive to change (12). The
SAQ summary score (SAQSS) averages the domains of
angina limitation, frequency, and quality of life to
provide an overall metric of angina severity (13). Full
details about patient-reported outcome measure as-
sessments are available in the Online Appendix.
All of the randomized participants were invited
to attend for a 1-year follow-up visit in person. The
same questionnaire set was completed before the
visit. The 1-year visit included 2 additional validated
questionnaires to gain insights into exercise and
functional capacity. Height, weight, resting pulse
rate, and blood pressure (BP) were measured. BP was
measured after 5 min of rest in the seated position
using a validated oscillometric automated office BP
device. If patients declined or were unable to attend
at 12 months, the questionnaires were sent with a pre-
paid return envelope. Follow-up questionnaires were
verified and scored by a blinded member of the
research team.
CLINICAL EVENTS. An independent clinical endpoints
committee adjudicated MACE in line with the pre-
defined charter. MACE were defined as all-cause
death, stroke or transient ischemic attack, unstable
angina requiring hospitalization, heart failure
requiring hospitalization, or nonfatal myocardial
infarction. The definitions for each event are listed
in the clinical endpoints committee charter (Online
Appendix). Follow-up assessments for serious ad-
verse events were performed up to January 2019. The
assessments were performed using electronic National
Health Service, a nationwide electronic portal, and
sourced individual patient case notes as appropriate.
1-YEAR OUTCOMES. Pr imary efficacy endpoint .
The primary outcome of this pre-specified analysiswas angina severity according to the SAQSS at 1
year (13).
Secondary efficacy endpoints . Secondary efficacy
endpoints were: 1) health status (including quality of
life); 2) lifestyle factors (smoking, weight, BP, and
cardiac rehabilitation attendance); 3) physical activity
and functional capacity; and 4) MACE.
STATISTICAL METHODS. The study design and sam-
ple size calculation have been previously described (7).
Health status change from baseline in other do-
mains was analyzed per the primary outcome incor-
porating baseline score and 6-month score in a
mixed-effects linear regression model. The methods
are described in the Online Appendix. We performed
2-tailed analyses and considered a p value #0.05 to
indicate statistical significance. Statistical analyses
were performed using R version 3.4.1 (R Foundation
for Statistical Computing, Vienna, Austria).
RESULTS
Between November 2016 and December 2017, we
enrolled 391 of 1,386 screened patients (28%) who had
been electively referred for invasive coronary
angiography with suspected angina (Figure 1). The
baseline characteristics of the participants are
described in Table 1.
The majority of the participants were women
(n ¼ 111 [74%]), and the median age was 61 years.
There was a high prevalence of cardiovascular risk
factors and preventive medicines, in keeping with an
elevated 10-year risk for coronary heart disease
events (median 18.6%). Antianginal therapy was
commonly prescribed (beta-blockers in 101 [67%],
long-acting nitrates in 71 [47%], and calcium-channel
blockers in 52 [34%]). At randomization, the majority
of subjects had daily or weekly angina (SAQ fre-
quency score #60), associated with mild to moderate
angina limitation (SAQ limitation mean 52.1  24.4).
Prior noninvasive stress test results were abnormal
in 47% (45 of 95) and 52% (30 of 58) of patients
who had abnormal results on exercise stress electro-
cardiography and radionuclide myocardial perfusion
imaging, respectively (Table 1). The mean exercise
duration was 6.3  2.6 min with the standard Bruce
treadmill exercise test protocol.
Coronary angiography revealed obstructive CAD
in 206 patients (53.7%), and 151 of 181 patients (83%)
with no obstructive CAD were randomized (n ¼ 75 to
the intervention group, n ¼ 76 to the blinded control
group). The left anterior descending coronary artery
was the target in 88% (n ¼ 132), the right coronary
artery in 12 (8%), and the circumflex coronary artery
TABLE 1 Baseline Characteristics
Randomized
All Patients
(N ¼ 151)
Control
(n ¼ 76)
Intervention
(n ¼ 75)
Age, yrs 61.0 (53.0–68.0) 60.0 (53.0–68.0) 62.0 (53.5–69.0)
Female 111 (73.5) 58 (76.3) 53 (70.7)
BMI, kg/m2 29.7 (25.6–34.7) 29.7 (25.6–34.0) 29.6 (25.7–34.8)
Current smoker 27 (17.9) 14 (18.4) 13 (17.3)
Previous myocardial infarction 24 (15.9) 13 (17.1) 11 (14.7)
Previous stroke or TIA 20 (13.2) 13 (17.1) 7 (9.3)
Diabetes mellitus 29 (19.2) 15 (19.7) 14 (18.7)
Dyslipidemia 120 (79.5) 61 (80.3) 59 (78.7)
Family history of CVD 105 (69.5) 51 (67.1) 54 (72.0)
Predicted 10-yr CHD risk* 18.6 (10.6–31.4) 18.1 (9.7–27.9) 19.0 (11.9–38.9)
Aspirin 131 (86.8) 67 (88.2) 64 (85.3)
Beta-blocker 101 (66.9) 51 (67.1) 50 (66.7)
Calcium-channel blocker 52 (34.4) 28 (36.8) 24 (32.0)
Nitrates 71 (47.0) 38 (50.0) 33 (44.0)
Statin 126 (83.4) 66 (86.8) 60 (80.0)
Nicorandil 26 (17.2) 15 (19.7) 11 (14.7)
ACE inhibitor or angiotensin
receptor blocker
68 (45.0) 35 (46.1) 33 (44.0)
Total cholesterol, mmol/l 3.55  0.98 3.57  1.06 3.52  0.90
HDL cholesterol, mmol/l 1.2  0.4 1.2  0.3 1.2  0.4
Baseline angina questionnaire:
nonanginal
0 0 0
Definite (typical) angina 97 (64.2) 42 (55.3) 55 (73.3)
Probable (atypical) angina 54 (35.8) 34 (44.7) 20 (26.7)
Seattle Angina Questionnaire
Angina summary score 50.8  18.1 49.0  17.2 52.6  18.9
Angina limitation 52.1  24.4 52.4  24.3 51.9  24.7
Angina stability 44.7  24.4 41.4  25.3 48.0  23.2
Angina frequency 59.3  23.5 54.9  21.3 63.7  25.0
Angina treatment
satisfaction
81.9  19.5 81.9  20.0 81.8  19.1
Angina quality of life 40.9  21.7 39.7  21.7 42.1  21.9
Quality of life (EQ-5D-5L)
Index score 0.60  0.29 0.58  0.30 0.62  0.28
VAS score 66.3  20.5 67.9  21.1 64.6  19.8
Stress electrocardiography
(performed)
95 (62.9) 46 (60.5) 49 (65.3)
Negative (normal) 13 (13.7) 6 (13.0) 7 (14.3)
Inconclusive 37 (39.0) 18 (39.1) 19 (38.8)
Abnormal 45 (47.4) 22 (47.8) 23 (46.9)
Radionuclide myocardial
perfusion (performed)
58 (38.4) 30 (39.5) 28 (37.3)
Negative or inconclusive 28 (48.3) 17 (56.7) 11 (39.3)
Abnormal 30 (51.7) 13 (43.3) 17 (60.7)
Values are median (interquartile range), n (%), or mean  SD. *ASSIGN risk score.
ACE ¼ angiotensin-converting enzyme; BMI ¼ body mass index; CHD ¼ coronary heart disease;
CVD ¼ cardiovascular disease; HDL ¼ high-density lipoprotein; TIA ¼ transient ischemic attack; VAS ¼ visual
analogue scale.
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37in 6 (4%). Within the randomized population, 74
participants (49%) underwent FFR assessment of
CAD as part of standard care. Thirty-four potentially
eligible patients were not randomized for logistical
and other reasons (Figure 1). The median FFR was
0.88 (interquartile range: 0.84 to 0.92). The median
procedure duration (entry to exit from the cardiac
catheterization laboratory) was 60 min. The IDP was
designed to be performed over an additional 20 min
relative to standard-care diagnostic coronary angi-
ography. The endotypes revealed by the IDP in the
randomized population included isolated MVA in 78
(52%), isolated VSA in 25 (17%), mixed (both) in 31
(20%), and noncardiac chest pain in 17 (11%). We
previously reported data at 6 months showing clin-
ical utility whereby in the intervention arm, physi-
cians were more inclined to include antianginal
therapy (87.8% vs. 48.7%; relative risk [RR]: 1.78;
95% confidence interval [CI]: 1.39 to 2.28; p < 0.001).
Additionally, in the intervention arm, physicians
were more likely to tailor angina therapy specifically
to treat a disorder of coronary artery function (86.5%
vs. 30.3%; RR: 2.82; 95% CI: 1.98 to 4.02; p < 0.001).
PRIMARY EFFICACY ENDPOINT: ANGINA AT 1 YEAR.
One hundred forty-two subjects (94%) completed the
1-year primary outcome assessment (SAQ). No pa-
tients were lost to follow-up, and 2 patients (1.3%)
died before 1-year follow-up; details of non-
responders are outlined in Figure 1. For the primary
endpoint, the SAQSS at 1 year was 27% higher in the
intervention group compared with the control group
(adjusted mean difference 13.6 units; 95% CI: 7.3 to
19.9; p < 0.001). In practical terms, we observed
further separation of angina scores between the 6-
month and 1-year time points, representing an in-
cremental difference of 2.3 units (Figure 2). The dif-
ferences were driven by reduced angina limitation
(14.5 units [28%]; 95% CI: 7.9 to 21.1; p < 0.001),
reduced angina frequency (9.5 units [16%]; 95% CI: 1.1
to 17.9; p ¼ 0.027), and improved angina-related
quality of life (13.6 units [33%]; 95% CI: 7.3 to 19.9;
p < 0.001). The individual components of the primary
outcome are shown in Table 2 and Figure 2. Subjects
with more severe angina (SAQSS below the median)
and with more severe psychological distress at base-
line had a tendency toward greater improvement in
angina with the intervention. There was no interac-
tion between sex, diabetes, or baseline illness
perception score with treatment effect.
SUBGROUP ANALYSIS. The subgroup analysis for the
interaction of baseline characteristics and estimated
treatment effect is shown in Figure 3. There were
clinically relevant between-group differences inprescribed therapies stratified by endotype at
12 months. Patients in the intervention arm with VSA
were more likely to be taking calcium-channel an-
tagonists at 12 months compared with those in the
control arm, whereas patients with MVA were more
FIGURE 2 Primary Efficacy Endpoint: Quality of Life Mean Scores at Baseline and at 6 and 12 Months
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angina severity according to the Seattle Angina Questionnaire [SAQ] summary score). Higher scores represents better (less severe) angina.
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38likely to be taking beta-blockers and angiotensin-
converting enzyme inhibitors at 12 months
compared with those in the control arm (Table 3).
Interestingly, there was no significant treatment ef-
fect in the noncardiac chest pain group (95% CI: 6.9
to 34.2; p ¼ 0.212). Otherwise the MVA group seemed
to have the most statistically significant treatment
effect (2.0 to 20.1 units; p ¼ 0.019). Nevertheless, a
subgroup analysis in this small study is underpow-
ered, while overall estimated average treatment ef-
fect between the groups was numerically similar but
with wider CIs in the smaller groups.
SECONDARY EFFICACY ENDPOINTS. Health status
(including quality of life). Patient-reported quality of
life at 1 year according to the EQ-5D-5L visualanalogue scale was significantly improved in the
intervention group (difference 13.0 units [20%];
95% CI: 6.7 to 19.3; p < 0.001). Similarly, the EQ-5D-5L
index also improved in the intervention relative to
control group (mean difference 0.11 units [18%];
95% CI: 0.03 to 0.19; p ¼ 0.010) (Figure 2). Patient
global treatment satisfaction was 44% higher in the
intervention group (24.5 units; 95% CI: 16.0 to 32.9;
p < 0.001; Figure 2). Illness perception scores were
significantly lower at 1 year, reflecting a less threat-
ening perception of illness in the intervention group
relative to control (9.8 units [22%]; 95% CI: 14.6
to 5.1; p < 0.001). There were no between-group
differences in psychological distress scores at
follow-up (Patient Health Questionnaire 4 treatment
effect 0.2 units; 95% CI: 1.3 to 0.90; p ¼ 0.715).
TABLE 2 Primary Outcome and Changes in Health Status at 1 Year
Control (n ¼ 76) Intervention (n ¼ 75) Treatment Effect at 6 Months Treatment Effect at 1 Year
12 Months D Baseline 12 Months D Baseline Estimate 95% CI p Value Estimate 95% CI p Value
Primary efficacy endpoint:
Seattle Angina
Questionnaire
Summary score 54.2 (24.1) 5.2 (18.0) 72.8 (21.3) 18.4 (21.4) 11.4 5.1 to 17.6 <0.001 13.6 7.3 to 19.9 <0.001
Limitation 51.8 (26.5) 1.6 (16.2) 67.4 (26.0) 12.4 (21.1) 14.5 8.0 to 21.0 <0.001 14.5 7.9 to 21.1 <0.001
Stability 47.6 (22.0) 6.4 (29.3) 56.3 (22.6) 7.4 (30.9) 4.2 5.7 to 14.2 0.404 1.9 8.2 to 12.0 0.716
Frequency 60.8 (27.8) 6.4 (25.3) 80.2 (20.9) 14.7 (27.1) 9.2 0.9 to 17.5 0.030 9.5 1.1 to 17.9 0.027
Satisfaction 80.5 (22.0) 1.6 (27.9) 94.6 (12.1) 11.7 (18.0) 12.0 5.1 to 19.0 0.001 13.6 6.6 to 20.6 <0.001
SAQ QoL 50.9 (26.1) 11.2 (25.1) 71.9 (24.9) 29.7 (23.6) 11.4 5.1 to 17.6 <0.001 13.6 7.3 to 19.9 <0.001
Secondary efficacy
endpoints: health
status
Systolic BP 148.5 (25.3) 15.8 (25.6) 141.8 (22.7) 1.3 (22.3) — — — 11.9 19.3 to 4.5 0.002
Diastolic BP 79.2 (11.0) 8.2 (14.9) 75.9 (11.7) 0.4 (11.7) — — — 4.8 8.5 to 1.1 0.011
Weight, kg 83.5 (18.1) 1.2 (4.6) 84.2 (20.3) 0.2 (11.4) — — — 1.26 4.2 to 1.7 0.403
BMI, kg/m2 31.0 (6.7) 0.5 (1.9) 30.2 (7.7) 0.0 (4.6) — — — 0.5 1.7 to 0.7 0.407
Quality of life (EQ-5D-5L)
Index score 0.58 (0.34) 0.01 (0.25) 0.74 (0.24) 0.09 (0.24) 0.10 0.02 to 0.17 0.019 0.11 0.03 to 0.19 0.010
VAS score 67 (22) 2 (19) 76 (17) 11 (23) 14.5 8.3 to 20.8 <0.001 13.0 6.7 to 19.3 <0.001
Illness perception* 41 (15) 2 (17) 34 (14) 11 (13) 8.3 13.0 to 3.7 <0.001 9.8 14.6 to 5.1 <0.001
Psychological distress 4.3 (4.3) 0.5 (3.6) 2.9 (3.6) 0.7 (3.2) 0.1 1.2 to 1.0 0.869 0.2 1.3 to 0.9 0.715
Treatment satisfaction
Effectiveness 65 (21) 6 (24) 77 (22) 20 (27) 11 3 to 19 0.006 13 6 to 21 0.001
Convenience 70 (22) 4 (22) 86 (16) 18 (20) 14 8 to 21 <0.001 21 14 to 27 <0.001
Global score 59 (27) 0 (26) 78 (21) 26 (27) 17 8 to 25 <0.001 24 16 to 33 <0.001
Treatment effect represents adjusted mean difference at follow-up derived using linear mixed model (intervention  control). *Illness perception. A higher score reflects a more threatening view of the
illness.
BIPQ ¼ Brief Illness Perception Score; BMI ¼ body mass index; BP ¼ blood pressure; CI ¼ confidence interval; QoL ¼ quality of life; SAQ ¼ Seattle Angina Questionnaire (lower scores represent worse
angina symptoms); VAS ¼ visual analogue score of EQ-5D validated quality-of-life tool (higher scores indicate better quality of life).
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39Lifestyle factors: weight, BP, cardiac rehabilitation,
and smoking. One hundred thirty-three subjects (88%)
attended the 1-year study assessment for in-person BP
and anthropometric measurements. Systolic and dia-
stolic BPs were both lower in the intervention group at
1-year follow-up (systolic BP 11.9 mm Hg;
95% CI: 19.3 to 4.5 mm Hg; p ¼ 0.002; diastolic
BP4.8mmHg; 95%CI:8.5 to1.1mmHg; p¼0.011).
Importantly, this effect was associated with a rise in
systolic BP from baseline in the control group (median
13.5 mm Hg), whereas there was only a modest
decrease in the systolic BP change from baseline in the
intervention group (median 2 mm Hg). Patient
participation at cardiac rehabilitationwas higher in the
intervention group (40% vs. 16%; RR: 2.53; 95% CI: 1.41
to 4.56; p¼0.001). Active smoking at 1 year was similar
between the groups (12% vs. 15%; RR: 0.84; 95% CI:
0.37 to 1.91; p ¼ 0.678). The adjusted mean difference
in weight from baseline to 1 year was not statistically
significant between the intervention (0.2 kg) and
control (1.2 kg) groups (estimated treatment
effect 1.26 kg; 95% CI: 4.23 to 1.71; p ¼ 0.403). Body
mass index change was not statistically different be-
tween the groups (0.51 kg/m2; 95% CI: 1.71 to
0.70 kg/m2; p ¼ 0.407).Phys ica l act iv i ty and funct iona l capac i ty .
Physical activity assessed using the International
Physical Activity Questionnaire–Short Form at
12 months was numerically higher in the intervention
group at follow-up, but the differences were not sta-
tistically significant different between the groups
(total exercise metabolic equivalent minutes per
week [intervention vs. control] median 1,386 vs.
1,188; p ¼ 0.072). Categorization into moderate and
high physical activity levels was also not different
between the groups (60% moderate/high in inter-
vention group vs. 51% in control group; RR: 1.19;
95% CI: 0.88 to 1.61; p ¼ 0.266).
Estimated functional capacity from the Duke Ac-
tivity Status Index was not different (6.2  2.0 vs. 5.7
 1.9; p ¼ 0.102). The overall Duke Activity Status
Index score was 4.5 units higher in the intervention
group compared with the control group (95% CI: 0.9
to 9.8; p ¼ 0.102), but this result was not statistically
significant.
MACE. During a median period of 19 months (inter-
quartile range: 16 to 22 months), 9 subjects (12%) in the
intervention group and 8 (11%) in the control group
experienced MACE (p ¼ 0.803). Overall, 2 participants
(1%) died, 4 (3%) experienced nonfatal myocardial
FIGURE 3 Subgroups and Secondary Endpoints: Weight, BP, and Physical Activity
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TABLE 4 Secondary Endpoints: Physical Activity, Health Promotion, and Clinical Events
Control
(n ¼ 76)
Intervention
(n ¼ 75) p Value
Physical activity (12 months)
Physical activity (IPAQ-SF)
MET minutes per week 1,188 (173–2,532) 1,386 (462–3,861) 0.072
Moderate or high physical activity
levels
36 (51) 38 (60) 0.528
Functional capacity (DASI)
Estimated peak VO2 19.9  6.5 21.8  6.9 0.102
Estimated METs 5.7  1.9 6.2  2.0 0.102
Overall DASI score 23.9  15.1 28.4  16.0 0.102
Cardiac rehabilitation 12 (16) 30 (40) 0.001
Smoking 11 (15) 9 (12) 0.811
Clinical events (19 months)*
MACE 8 (10.5) 9 (12.0) 0.803
Death 0 (0.0) 2 (2.7) 0.245
Myocardial infarction 2 (2.6) 2 (2.7) 1.000
Stroke/TIA 2 (2.6) 1 (1.3) 1.000
Unstable angina (hospitalization or
revascularization)
5 (6.6) 4 (5.3) 1.000
Heart failure (hospitalization) 0 (0.0) 2 (2.7) 0.245
Values are median (interquartile range), n (%), or mean  SD. Randomized groups were compared using Fisher
exact test for categorical variables and Student’s t-test for continuous variables. The median duration of follow-
up was 19 months (range: 16 to 22 months). Causes of death in patients were cardiovascular (heart failure, n ¼ 1)
and noncardiovascular (cancer, n ¼ 1). *Mann-Whitney Wilcoxon test. Bold indicates p < 0.05.
DASI ¼ Duke Activity Status Index (estimates functional capacity); IPAQ-SF ¼ International Physical Activity
Questionnaire–Short Form; MACE ¼ major adverse cardiac events; MET ¼ metabolic equivalent units;
TIA ¼ transient ischemic attack; VO2 ¼ maximum rate of oxygen consumption measured during incremental
exercise; other abbreviations as in Tables 1 and 3.
TABLE 3 Prescribed Therapies According to Randomized Group and Diagnosis Revealed by IDP
Noncardiac MVA VSA Mixed (MVA and VSA)
Intervention
(n ¼ 6)
Control
(n ¼ 11) p Value
Intervention
(n ¼ 43)
Control
(n ¼ 35) p Value
Intervention
(n ¼ 12)
Control
(n ¼ 13) p Value
Intervention
(n ¼ 14)
Control
(n ¼ 17) p Value
Aspirin 1 (16.7) 7 (63.6) 0.131 30 (69.8) 19 (54.3) 0.239 11 (91.7) 7 (53.8) 0.073 12 (85.7) 13 (76.5) 0.664
Beta-blocker 1 (16.7) 7 (63.6) 0.131 29 (67.4) 15 (42.9) 0.039 2 (16.7) 6 (46.2) 0.202 7 (50.0) 12 (70.6) 0.288
CCB 2 (33.3) 5 (45.5) 1.000 20 (46.5) 10 (28.6) 0.160 7 (58.3) 2 (15.4) 0.041 8 (57.1) 3 (17.6) 0.031
Nitrates 0 (0.0) 3 (27.3) 0.515 8 (18.6) 13 (37.1) 0.078 9 (75.0) 4 (30.8) 0.047 9 (64.3) 5 (29.4) 0.076
Nitroglycerin 4 (66.7) 5 (45.5) 0.620 37 (86.0) 21 (60.0) 0.018 10 (83.3) 7 (53.8) 0.202 14 (100.0) 6 (35.3) <0.001
Nicorandil 0 (0.0) 1 (9.1) 1.000 8 (18.6) 6 (17.1) 1.000 4 (33.3) 4 (30.8) 1.000 3 (21.4) 2 (11.8) 0.636
ACE inhibitor or ARB 3 (50.0) 7 (63.6) 0.644 26 (60.5) 11 (31.4) 0.013 5 (41.7) 4 (30.8) 0.688 10 (71.4) 7 (41.2) 0.149
Statin 2 (33.3) 8 (72.7) 0.162 37 (86.0) 20 (57.1) 0.005 11 (91.7) 8 (61.5) 0.160 13 (92.9) 10 (58.8) 0.045
Ranolazine 0 (0.0) 0 (0.0) 1.000 0 (0.0) 2 (5.7) 0.198 0 (0.0) 0 (0.0) 1.000 1 (7.1) 0 (0.0) 0.452
Ivabradine 0 (0.0) 0 (0.0) 1.000 0 (0.0) 1 (2.9) 0.449 1 (8.3) 1 (7.7) 1.000 0 (0.0) 1 (5.9) 1.000
Values are n (%) unless otherwise indicated. Randomized groups were compared using Fisher exact tests without multiplicity correction. Bold indicated significance between group differences in therapies at
six months.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CCB ¼ calcium-channel blocker; IDP ¼ interventional diagnostic procedure; MVA ¼ microvascular angina; VSA ¼ vasospastic
angina.
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41infarction, 3 had cerebrovascular events (2%), 2 (1%)
were hospitalized for heart failure, and 9 (6%) expe-
rienced unstable angina requiring urgent revascular-
ization or hospitalization. Causes of death were
cardiac (heart failure, n ¼ 1) and noncardiac (malig-
nancy, n ¼ 1). These events are detailed in Table 4.
There were no between-group differences in any of
the MACE subtypes during longer term follow-up.
DISCUSSION
We found that angina severity, quality of life, treat-
ment satisfaction, and illness perception improved at
1 year in the stratified therapy intervention group
relative to control. We observed mechanistic differ-
ences that help explain the treatment effect, notably
appropriate stratification of therapy, lower systolic
and diastolic BPs relative to control, enhanced
participation in cardiac rehabilitation, and nonsig-
nificant trends toward improved functional capacity
and physical activity levels in the intervention group
(Central Illustration). There were no procedural safety
concerns, and MACE were appreciable in the ran-
domized population, with no significant between-
group differences.
The 1-year difference in angina severity reflected
progressive differences over time associated with
stratified therapy. The magnitude of the treatment
effect relative to the baseline score (14 units of the
SAQSS; 95% CI: 7 to 20 units; p < 0.001) represented a
27% higher overall angina score. This is consistent
with 1 grade in the Canadian Cardiovascular Society
classification and a clinically meaningful difference
for patients (14). This improvement is greater thanthe minimum clinically important difference of 8
points for the SAQ angina limitation, frequency, and
quality-of-life domains and 5 points for SAQ treat-
ment satisfaction (15). The increment from baseline to
1 year in the EQ-5D-5L index was 0.06 units (95% CI:
0.00 to 0.21), and the treatment effect (between-
group difference) was 0.11 units (95% CI: 0.03 to 0.19;
p ¼ 0.010). The ORBITA trial enrolled patients with
CENTRAL ILLUSTRATION Invasive Coronary Function Testing in Angina (CorMICA): 1-Year RCT Outcomes
Ford, T.J. et al. J Am Coll Cardiol Intv. 2020;13(1):33–45.
CAD ¼ coronary artery disease; CorMICA ¼ Coronary Microvascular Angina; RCT ¼ randomized controlled trial.
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42obstructive CAD, and patients randomized to percu-
taneous coronary intervention had a 1-month incre-
ment of 0.03 units (95% CI: 0.00 to 0.06), with no
between-group difference between percutaneous
coronary intervention and sham control (16). CorMicA
participants had a much higher burden of health
impairment (SAQ and EQ-5D), potentially indicating
greater scope for health gain from a personalized
intervention including cardiac rehabilitation. We
observed a significant interaction between psycho-
logical distress at baseline and subsequent treatment
response, highlighting the importance of addressing
psychological factors that contribute to patients’
experience of angina (17).PHARMACOLOGICAL TREATMENT EFFECT. Stratified
medicine is the identification of key subgroups of
patients (endotypes) within an undifferentiated,
heterogeneous population, these endotypes (MVA,
VSA, both, or none) being distinguishable by distinct
mechanisms of disease and/or responses to therapy
(18). We observed between-group differences in
medical therapies by endotype at 1 year, indicating
personalized therapy. In addition, there were more
prescribed antianginal and ischemic heart disease
therapies in the intervention group at 1 year (median
4 [interquartile range: 3 to 5] vs. 3 [interquartile
range: 1 to 4] in the control group). Improvements in
health status may in part relate to higher use of
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43angiotensin-converting enzyme inhibitors and sta-
tins, agents with disease-modifying properties with
plausible benefits on microcirculatory and endothe-
lial function (19,20). Resting systolic and diastolic BPs
were lower at 1 year in the intervention group, an
effect that could be mediated by a combination of a
larger number of antianginal therapies, better
therapy compliance, and less inappropriate cessation
of therapy.
NONPHARMACOLOGICAL TREATMENT EFFECT.
Patients with newly diagnosed angina or ischemic
heart disease may benefit from cardiac rehabilitation,
and we observed more than 2-fold use in the inter-
vention group (40% vs. 16%; RR: 2.53; 95% CI: 1.41 to
4.56; p ¼ 0.001). Cardiac rehabilitation improves
functional and physical exercise capacities and may
have important psychological benefits, helping pa-
tients understand their illness (21). One-half of all
participants had body mass index >30 kg/m2 at
baseline, and we did not observe any significant
between-group differences in weight or body mass
index at 1-year follow-up. Interestingly, there was a
trend toward a higher treatment response in
extremely obese patients (body mass index
>35 kg/m2), which could be the focus of further
research. Strategies of intensive weight loss have
shown disease-modifying properties in people with
diabetes (22).
Angina symptoms are often subjective and
multifactorial in origin; listening to patients and
providing education and explanation or validation
of symptoms may facilitate improvement in angina
(23). Indeed, it is impossible to fully separate the
impact of a definitive diagnosis on symptoms and
the benefits achieved related solely to pharmaco-
logical therapy. A conclusive diagnosis may be
therapeutic in itself (24). The effect of having a
diagnosis may motivate patients to modify lifestyle
and possibly improve compliance to a much
greater extent than those in the control group, who
did not have the benefit of receiving a correct
diagnosis. Illness perception may be more threat-
ening in patients with diagnostic uncertainty, and
this is an important predictor of longer term
disability and not returning to work (25).
STUDY LIMITATIONS. First, we adopted binary cut-
offs for the IDP test results in line with guidelines and
established diagnostic thresholds. The optimal prog-
nostic thresholds for these parameters of ischemia
(e.g., CFR, index of microcirculatory resistance, ACh
response) are part of a continuum. It is possible that
indeterminate (gray-zone or borderline) test results
may be misclassified (26). Nevertheless, we adopted astringent approach using unambiguous reference
thresholds for disease classification (e.g., CFR cutoff
of 2.0 rather than 2.5). The IDP was focused on a
single major coronary artery for pragmatic reasons to
avoid unnecessarily prolonging the procedure. In
patients with microvascular disease, regional varia-
tions in myocardial blood flow at rest and during
pharmacological hyperemia may be detected by
quantitative imaging with positron emission tomog-
raphy and cardiac magnetic resonance (6,27). Impor-
tantly, these noninvasive tools have not been
validated for diagnosing vasospastic disorders.
Second, we performed ACh provocation testing
after the administration of glyceryl trinitrate for
assessment of coronary function during adenosine-
induced hyperemia. There is no firm consensus on
the timing of whether ACh testing should be before or
after adenosine testing. We advocate ACh testing
after adenosine because a markedly positive result
for vasospasm may confound the assessment of
resting blood flow because of elevated sympathetic
drive (i.e., CFR may be falsely lowered). In contrast,
the half-life of glyceryl trinitrate is about 2 min (28),
and a false-negative result for coronary vasospasm is
thus unlikely following the first stage of the IDP
(adenosine).
Finally, a simple and pragmatic approach would be
to treat all patients with possible angina and non-
obstructive CAD with an additional antianginal ther-
apy as a therapeutic trial. As clinical researchers, we
believe that a person-centered approach is para-
mount. Optimizing therapy to a specific diagnosis and
avoiding harm from unnecessary long-term poly-
pharmacy will benefit patients and health care pro-
viders. Furthermore, stratifying this undifferentiated
patient cohort paves the way for developing
disease-modifying therapy. In this regard, we have
shown that endothelial dysfunction and endothelin-1
dysregulation are important and may represent po-
tential therapeutic targets for patients with symp-
toms and/or signs of ischemia and no obstructive CAD
(29). CorMicA highlights the limitations of anatomic
tests for identifying coronary vasomotion disorders.
Indeed, anatomic testing (e.g., computed tomo-
graphic coronary angiography) may result in false
reassurance for patients with no obstructive CAD but
underlying MVA and/or VSA. These patients are pre-
dominantly women (30). Discontinuation of therapy
by protocol in patients with undiagnosed MVA may
be one explanation for why management guided by
computed tomographic coronary angiography is
associated with more angina and worse health-
related quality of life compared with standard
care (31).
PERSPECTIVES
WHAT IS KNOWN? In patients with angina, strati-
fied medicine improves angina and quality of life in
the short term. Whether these improvements are
sustained in the longer term is unknown.
WHAT IS NEW? Invasive coronary physiology can
help to identify distinct treatable subgroups within
the angina population without obstructive CAD.
Stratified medicine led to sustained improvements
in angina and well-being. Mechanisms included
diagnostic reclassification with linked therapy
including cardiac rehabilitation.
WHAT IS NEXT? More trials are needed to extend
external validity and expand the evidence base.
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44CONCLUSIONS
Invasive coronary physiological assessment allows
stratified medical therapy, representing an opportu-
nity for better long-term angina treatment in patients
without obstructive CAD. Larger multicenter trials
and cost-effectiveness analyses are needed.
ACKNOWLEDGMENTS The authors acknowledge the
patients, the staff members, and the British Heart
Foundation, who supported this study. The authors
appreciate the trial clinical events committee, including
Dr. Andrew Hannah and Dr. Andrew Stewart.
ADDRESS FOR CORRESPONDENCE: Prof. Colin
Berry, British Heart Foundation Glasgow Cardiovas-
cular Research Centre, Institute of Cardiovascular and
Medical Sciences, 126 University Place, University of
Glasgow, Glasgow, G12 8TA, United Kingdom. E-mail:
colin.berry@glasgow.ac.uk.RE F E RENCE S1. Patel MR, Peterson ED, Dai D, et al. Low diag-
nostic yield of elective coronary angiography.
N Engl J Med 2010;362:886–95.
2. Maddox TM, Stanislawski MA, Grunwald GK,
et al. Nonobstructive coronary artery disease and
risk of myocardial infarction. JAMA 2014;312:
1754–63.
3. Tavella R, Cutri N, Tucker G, Adams R,
Spertus J, Beltrame JF. Natural history of pa-
tients with insignificant coronary artery disease.
Eur Heart J Qual Care Clin Outcomes 2016;2:
117–24.
4. Jespersen L, Hvelplund A, Abildstrom SZ, et al.
Stable angina pectoris with no obstructive coro-
nary artery disease is associated with increased
risks of major adverse cardiovascular events. Eur
Heart J 2012;33:734–44.
5. Suda A, Takahashi J, Hao K, et al. Coronary
functional abnormalities in patients with angina
and nonobstructive coronary artery disease. J Am
Coll Cardiol 2019;74:2350–60.
6. Ford TJ, Berry C, De Bruyne B, et al. Physiological
predictors of acute coronary syndromes: emerging
insights from the plaque to the vulnerable patient.
J Am Coll Cardiol Intv 2017;10:2539–47.
7. Ford TJ, Corcoran D, Oldroyd KG, et al. Ratio-
nale and design of the British Heart Foundation
(BHF) Coronary Microvascular Angina (CorMicA)
stratified medicine clinical trial. Am Heart J 2018;
201:86–94.
8. Ford TJ, Stanley B, Good R, et al. Stratified
medical therapy using invasive coronary function
testing in angina: the CorMicA trial. J Am Coll
Cardiol 2018;72:2841–55.
9. Rose G, McCartney P, Reid DD. Self-
administration of a questionnaire on chest pain
and intermittent claudication. Br J Prev Soc Med
1977;31:42–8.10. Task Force M, Montalescot G, Sechtem U,
et al. 2013 ESC guidelines on the management of
stable coronary artery disease: the Task Force on
the Management of Stable Coronary Artery Dis-
ease of the European Society of Cardiology. Eur
Heart J 2013;34:2949–3003.
11. Beltrame JF, Crea F, Kaski JC, et al. Interna-
tional standardization of diagnostic criteria for
vasospastic angina. Eur Heart J 2017;38:2565–8.
12. Spertus JA, Winder JA, Dewhurst TA, et al.
Development and evaluation of the Seattle Angina
questionnaire: a new functional status measure for
coronary artery disease. J Am Coll Cardiol 1995;25:
333–41.
13. Chan PS, Jones PG, Arnold SA, Spertus JA.
Development and validation of a short version of
the Seattle Angina Questionnaire. Circ Cardiovasc
Qual Outcomes 2014;7:640–7.
14. Spertus JA, Arnold SV. The evolution of
patient-reported outcomes in clinical trials and
management of patients with coronary artery
disease: 20 years with the Seattle Angina Ques-
tionnaire. JAMA Cardiol 2018;3:1035–6.
15. Spertus JA, Winder JA, Dewhurst TA, Deyo RA,
Fihn SD. Monitoring the quality of life in patients
with coronary artery disease. Am J Cardiol 1994;
74:1240–4.
16. Al-Lamee R, Thompson D, Dehbi HM, et al.
Percutaneous coronary intervention in stable
angina (ORBITA): a double-blind, randomised
controlled trial. Lancet 2018;391:31–40.
17. Sullivan MD, Ciechanowski PS, Russo JE, et al.
Angina pectoris during daily activities and exercise
stress testing: the role of inducible myocardial
ischemia and psychological distress. Pain 2008;
139:551–61.
18. The MRC Framework for the Development,
Design and Analysis of Stratified MedicineResearch. London: Medical Research Council;
2018.
19. Fearon WF, Okada K, Kobashigawa JA, et al.
Angiotensin-converting enzyme inhibition early
after heart transplantation. J Am Coll Cardiol
2017;69:2832–41.
20. Ong P, Athanasiadis A, Sechtem U. Pharma-
cotherapy for coronary microvascular dysfunction.
Eur Heart J Cardiovasc Pharmacother 2015;1:
65–71.
21. Anderson L, Thompson DR, Oldridge N, et al.
Exercise-based cardiac rehabilitation for coronary
heart disease. Cochrane Database Syst Rev 2016;1:
CD001800.
22. Lean MEJ, Leslie WS, Barnes AC, et al. Primary
care-led weight management for remission of type
2 diabetes (DiRECT): an open-label, cluster-
randomised trial. Lancet 2018;391:541–51.
23. Kirtane AJ. The importance of listening to
patients: the Seattle Angina Questionnaire. JAMA
Cardiology 2018;3:1037.
24. Kirtane AJ. ORBITA2. Circulation 2018;138:
1793–6.
25. Petrie KJ, Weinman J, Sharpe N, Buckley J.
Role of patients’ view of their illness in predicting
return to work and functioning after myocardial
infarction: longitudinal study. BMJ 1996;312:
1191–4.
26. Aziz A, Hansen HS, Sechtem U, Prescott E,
Ong P. Sex-related differences in vasomotor
function in patients with angina and unobstructed
coronary arteries. J Am Coll Cardiol 2017;70:
2349–58.
27. Kaski JC, Crea F, Gersh BJ, Camici PG. Reap-
praisal of ischemic heart disease. Circulation 2018;
138:1463–80.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 3 , N O . 1 , 2 0 2 0 Ford et al.
J A N U A R Y 1 3 , 2 0 2 0 : 3 3 – 4 5 CorMicA 1-Year Results
4528. Bogaert MG. Clinical pharmacokinetics of
glyceryl trinitrate following the use of systemic
and topical preparations. Clin Pharmacokinet
1987;12:1–11.
29. Ford TJ, Rocchiccioli P, Good R, et al. Systemic
microvascular dysfunction in microvascular and
vasospastic angina. Eur Heart J 2018;39:4086–97.
30. Sheikh AR, Zeitz CJ, Rajendran S, Di Fiore DP,
Tavella R, Beltrame JF. Clinical and coronaryhaemodynamic determinants of recurrent chest
pain in patients without obstructive coronary ar-
tery disease—a pilot study. Int J Cardiol 2018;267:
16–21.
31. Williams MC, Hunter A, Shah A, et al. Symp-
toms and quality of life in patients with suspected
angina undergoing CT coronary angiography: a
randomised controlled trial. Heart 2017;103:
995–1001.KEY WORDS coronary physiology, elective
coronary angiography, microvascular angina,
stable angina pectoris, stratified medicine,
vasospastic angina
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